Morning Movers: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX), Atmel Corporation (NASDAQ:ATML), Home Loan Servicing Solutions, Ltd. (NASDAQ:HLSS), ON Semiconductor Corp. (NASDAQ:ONNN), Can-Fite BioPharma (NYSEMKT:CANF)

On Dec. 18, Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) announced that the application of European patent number 2,222,278 was allowed by the European Patent Office. The new patent, “Improved Taxane Delivery System,” covers the Company’s proprietary taxane prodrug nanoparticle delivery technology and CPX-8, a hydrophobic docetaxel prodrug nanoparticle, which is based on this innovative approach to drug delivery. Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) belongs to Healthcare sector. Its weekly performance is 12.00%. On last trading day company shares ended up $1.96. Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) distance from 50-day simple moving average (SMA50) is -0.21%.

Announced Dec 23, that Atmel Corporation (NASDAQ:ATML) recently entered into a strategic partnership with Fingerprint Cards AB (FPC) — a leader in fingerprint verification solutions, to bring cutting-edge biometric sensor and touch-screen solutions to smart mobile devices. Atmel Corporation (NASDAQ:ATML) shares decreased -0.06% in last trading session and ended the day at $8.40. ATML Gross Margin is 44.30% and its return on assets is 3.40%. Atmel Corporation (NASDAQ:ATML) quarterly performance is 5.33%.

Home Loan Servicing Solutions (NASDAQ:HLSS) has received an average recommendation of “Buy” from the nine brokerages that are currently covering the stock, AnalystRatingsNetwork reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. On 31 December, Home Loan Servicing Solutions, Ltd. (NASDAQ:HLSS) shares decreased -1.61% and was closed at $19.52. HLSS EPS growth in last 5 year was 40.89%. Home Loan Servicing Solutions, Ltd. (NASDAQ:HLSS) year to date (YTD) performance is -6.60%.

ON Semiconductor (NASDAQ:ONNN), driving energy efficiency innovations, has introduced a family of affordable, precision CMOS operational amplifiers (op amps) that deliver zero drift operation and industry leading quiescent current for front-end amplifier circuits and power management designs. Targeted at industrial, white goods, telecom, wearables, Internet-of-Things (IoT), test equipment and instrumentation applications, the NCS325 and NCS333 op amp devices enhance the accuracy of motor control feedback and power supply control loops, thereby contributing to higher overall system efficiency. ON Semiconductor Corp. (NASDAQ:ONNN) belongs to Technology sector. Its net profit margin is 7.20% and weekly performance is -0.39%. On last trading day company shares ended up $10.13. ON Semiconductor Corp. (NASDAQ:ONNN) distance from 50-day simple moving average (SMA50) is 13.07%.

On Dec 30, Can-Fite BioPharma Ltd. (NYSE:CANF) announced that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101. Dr. M. Silverman, Can-Fite Medical Director, and Dr. Lee Simon, a key opinion leader in the field of autoimmune inflammatory diseases, designed the Phase III clinical study. Can-Fite BioPharma Ltd. (NYSEMKT:CANF) shares advanced 2.34% in last trading session and ended the day at $3.50. Can-Fite BioPharma Ltd. (NYSEMKT:CANF) quarterly performance is 8.36%.